HTA for Medical Devices in APAC: Why Value, Evidence, and Local Relevance Likely to Decide the Next Wave of Adoption

In APAC, health technology assessment for medical devices is no longer just a reimbursement filter. It is becoming a powerful force that shapes how value is defined, what evidence matters, and which innovations actually scale. As markets across the region sharpen their HTA frameworks, the real challenge for MedTech companies is no longer proving that a device works but rather highlighting why it matters in the context of local health system priorities.

Asia Pacific is rather crucial for medical device companies to treat as a secondary market access story. In 2023, the APAC MedTech industry was estimated at USD 121 billion, with projections reaching roughly USD 140 billion by 2025. This growth story is as real as the complexity underlying it. The region combines large public systems, private provider-driven markets, emerging reimbursement structures, ageing populations, and rising demand for diagnostics, digital tools, and care models that can achieve more with constrained budgets.

This is why health technology assessment (HTA) is emerging as one of the most strategic disciplines for medical device companies in APAC. For several years, many manufacturers viewed HTA largely as a reimbursement or pricing checkpoint. At present, this view is extremely narrow in APAC. HTA is improving the focus through which governments, payers, and health systems decide not only whether a technology works but also whether it is worth funding, how it should be positioned, what evidence counts, and which benefits matter the most in each market. Singapore’s Health Technology Advisory Council (HTAC), formed on April 1, 2025, is one visible example of this shift: it was created to provide evidence-based recommendations on high-cost, high-impact health technologies for public funding decisions. Meanwhile, Australia is actively implementing reforms following its HTA Review, which produced 50 recommendations aimed at improving access, equity, and process efficiency.

Medical devices rarely fit neatly into traditional assessment logic, which is a challenge and an opportunity. Medicines can often be judged through relatively stable endpoints and trial structures while devices cannot. Outcomes may depend on operator learning, workflow redesign, site of care, interoperability, patient adherence, service support, and pace of product iteration. A diagnostic platform, a connected monitoring solution, an AI-enabled tool, and an implantable device may all fall under the same broad MedTech umbrella, each with a fundamentally different value story. This is why APAC device HTA deserves a more strategic conversation than it usually gets.

APAC Not a Single HTA Market; Treating it Like One Likely to be an Expensive Mistake

The first reality companies must internalize is that there is no sole APAC HTA strategy. APACMed’ s 2024 summary on medical device HTA makes this point clear. Australia, South Korea, and Japan may all be relatively advanced, but they materially differ in the methods, processes, and intended use of HTA in device reimbursement decisions. The report plainly states that no single HTA framework can be applied across markets. While this may sound obvious, in practice, many companies try to export one evidence package and one value narrative across the region, only to realize that the local decision logic does not line up.

Australia is a good example of why the local nuance matters. Its HTA reform agenda is not just administrative housekeeping. The government’s review concluded that the system should improve access, address inequity, and make processes easier for clinicians and consumers to engage with. The financial stakes are also clear. Under Australia’s Prescribed List  of Medical Devices and Human Tissue Products reforms, reimbursement for medical devices represented 14% of the health insurance expenditure. The reform program reported savings of AUD 195.9 million from 2023 to 2024 and AUD 105.7 million from 2022 to 2023. In such a market, companies are not simply trying to prove value in principle; rather, they are operating in a system where budget impact and policy design carry real weight.

Japan follows a different model. Formal cost effectiveness evaluation began in 2019, and it is mainly used to support price adjustments rather than to decide whether a technology is covered at all. This distinction is key. It means a company may achieve access, but the quality of its value narrative can materially influence the economics of that access. The Professional Society for Health Economics and Outcomes Research (ISPOR)’s recent discussion of Japan’s system highlights that in the first six years of the program, more than 40 products were assessed, with some resulting in reimbursement price adjustment. In practical terms, Japan checks whether companies have a reimbursement story and durable pricing story.

Although a small nation, Singapore is gaining importance due to how structured and disciplined its assessment architecture is becoming. The Agency for Care Effectiveness supports subsidy decisions for drugs and medical technologies, including devices, diagnostics, and medical services. The creation of the HTAC for high-cost, high-impact technologies signals a system that is becoming more deliberate about evaluating what public funding should support. The methods architecture is evolving as well. ACE’s methods page was updated in March 2026, and its medical technologies evaluation guide was updated in December 2025 to include a new addendum on digital health technologies under subsidy consideration. This is a meaningful signal in a region where digital and software-led technologies are expanding faster than many legacy funding models can comfortably accommodate.

While India sits at a different point on the maturity curve, it would be a mistake to dismiss it as a future story. Health Technology Assessment in India evaluates medicines, devices, and health programs for clinical effectiveness, cost effectiveness, and safety. Its official website reports 98 completed and 68 ongoing studies. Its completed work includes several device-related topics such as intraocular lenses, safety-engineered syringes, pulse oximeters, portable ventilators, PET plus CT, and proton technology equipment. This is key, as it shows that device assessment is part of the institutional agenda. Furthermore, it signals a broader shift from discussion to execution in India, especially as evidence is increasingly tied to policy and public resource allocation.

Markets with less mature formal frameworks are also moving in this direction. Indonesia’s Ministry of Health launched a “One Door, One Standard” HTA business process in October 2024, unifying applications for medical devices, diagnostics, and pharmaceuticals under a more coordinated system. By late 2025, officials publicly described HTA implementation as increasingly crucial and rapidly growing. This is the type of policy movement that companies need to read early, as markets that seem administratively fluid today can become more structured within a short strategic window.

Real Challenge in Device HTA is Not Lack of Evidence, but Lack of Evidence Fit

Typically, medical device companies do not face challenges due to the lack of evidence. They struggle as the evidence they have is often not the evidence that the local decision-makers find the most useful. This is one of the most important distinctions in APAC.

Devices are iterative. They improve overtime. Their performance is often shaped by operator training and institutional workflow. Their value may not appear as a clean change in a single endpoint but as shorter procedure times, fewer complications, reduced readmissions, lower staffing burden, improved patient throughput, or a shift of care from hospital to lower cost settings. Traditional HTA approaches can capture some but often not all of it and certainly not equally well across markets. APACMed’ s 2024 review directly reflects this tension in its comparison of device HTA across Australia, South Korea, and Japan.

The practical implication is that evidence planning cannot be left for the last stage of the commercialization journey. It must begin when the evidence strategy is designed. Companies must try to understand the knowledge gap in each market. Is the payer the most concerned about affordability at scale? Is the health system persuaded more by avoided utilization rather than incremental efficacy? Does the technology need local comparators, local cost inputs, or proof of operational impact in public hospitals rather than tertiary centers? In APAC, the difference between a persuasive value case and a technically sound but commercially weak one often lies in whether the evidence was shaped to answer local questions. This is why the report’s emphasis on methodological differences across markets is important.

Value in APAC Expanding Beyond Clinical Benefit and Acquisition Cost

One of the most important developments in the region is that the definition of value is being reexamined. Published in 2025, the BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region published by the Office of Health Economics reviews the state of broader value and societal perspective in APAC HTA. It reveals that only China and Thailand consider the societal perspective in the base case, while countries such as Australia, Vietnam, South Korea, and Malaysia may accept it in supplementary analyses. Other jurisdictions, including Singapore and Hong Kong, do not currently recognize it in their HTA guidelines. This implies that while broader value is not yet consistently embedded across the region, it is on the policy agenda.

Why does this matter for medical devices? Because many of the benefits that devices generate are broader than the direct clinical effect. A diagnostic may shorten the time to treatment selection, a monitoring technology may reduce preventable deterioration, and a procedural innovation may lower the nursing burden or reduce the hospital length of stay. Meanwhile, a digital tool may improve the continuity of care and reduce unnecessary visits. These are not merely side benefits. In strained health systems, they are often the benefits that determine whether a technology is truly useful.

The BRAVER report is crucial, as it provides structure to a mostly vague debate. It argues that broader value elements and a wider perspective are increasingly relevant in APAC due to demographic change, chronic disease burden, and dependence on unpaid care. In a region where the East Asia and Pacific population aged 65 years and above reached 325.9 million in 2024, this argument carries real urgency. Healthcare systems are being asked not only what they fund but also how intelligently they allocate scarce resources in the face of ageing and rising demand. This implies that the value story for device companies is becoming increasingly multidimensional.

Real World Evidence Becoming a Market Access Imperative, Not a Supporting Exhibit

If broader value is one major shift, real-world evidence (RWE) is the other. Across APAC, RWE is moving from a useful supplement to a central part of the access conversation.

APACMed’ s policy work in 2025 explicitly called for stronger generation and use of RWE to inform payer and policy decision-making. In March 2026, Singapore’s ACE went a step further by releasing a formal position statement on the use of real-world data and evidence to support HTA and funding decisions. These are strong signals that RWE is becoming institutionalized and not merely encouraged. The future direction is clear: APAC systems are becoming more open to evidence that reflects how technologies perform in actual practice, especially where traditional trial evidence is incomplete or poorly aligned to the policy question.

This shift is especially consequential for devices. Real-world data can answer questions that trials often cannot: how a technology performs in routine practice, how the results vary across provider settings, how quickly users move up the learning curve, and whether operational benefits actually appear at scale. For digital health, connected monitoring, and software-led tools, RWE may be essential rather than optional. This is one reason why APACMed’ s digital health platform is gaining prominence. Its digital health committee now includes 310+ members from 85+ MedTech companies, and the association continues to advocate for reimbursement frameworks that can accommodate AI-based platforms and other digital technologies across APAC.

There is a human side to this shift as well. Clinicians and payers often do not ask for perfect evidence. They ask for credible evidence that feels relevant to patients, hospitals, and operating conditions similar to theirs. RWE often becomes the bridge between technical promises and practical trust. In device HTA, this bridge is gaining importance with each passing year.

Final Thoughts

HTA for medical devices in APAC is no longer a narrow reimbursement exercise. It is becoming an influential mechanism in shaping which technologies gain traction, how value is defined, and what kind of evidence is required to support adoption. As outlined in this article, this shift is unfolding across a variable region. Australia is reforming its HTA architecture, Japan continues to use HTA in ways that directly influence pricing, Singapore is sharpening structured evaluation for high-impact technologies, India is steadily building institutional HTA capacity, and emerging markets such as Indonesia are moving toward more coordinated assessment processes.

The core HTA conversation in APAC is simultaneously evolving. The challenge for medical devices is not merely the availability of evidence but whether that evidence is suited to the realities of device performance, clinical workflows, and local decision-making. Broader definitions of value are beginning to gain ground, particularly as health systems face the challenges of ageing populations, rising chronic disease burden, and pressure to deliver more efficient care. RWE is becoming increasingly central, especially for devices and digital technologies whose impact is often best understood in routine practice rather than controlled trial settings alone. Taken together, these developments point to a clear direction. HTA in APAC is becoming more nuanced, locally specific, and closely linked to funding, pricing, and adoption decisions. For medical device companies, success in this region is likely to depend on not only technological innovation but also the ability to align that innovation with how different APAC markets define value, interpret evidence, and prioritize health system needs. In that sense, HTA is no longer just part of the access pathway. It is becoming one of the central forces shaping the future of MedTech adoption across APAC.